Your Followed Topics

28.7K est. views20.00%
business2d ago

https://www.cnbc.com/2025/10/14/jpmorgan-chase-jpm-earnings-q3-2025.htmlhttps://finance.yahoo.com/news/insmed-host-third-quarter-2025-110000218.htmlhttps://www.tradingview.com/news/tradingview:026c179b37c30:0-jpmorgan-chase-co-q3-2025-financial-results/
Cnbc.com and 5 more
www.cnbc.com
Open in Cnbc.com
Highlights
  • Pulmatrix's PUR3100 for acute migraine has an FDA-accepted IND and a planned Phase 2 study, contingent on financing or a partnership.
  • Pulmatrix’s iSPERSE2 tech aims to deliver small, dense particles to the airways, improving delivery while reducing systemic side effects.
  • With IND acceptance, PUR3100 could accelerate development if external funding or partnerships materialize.

Virality Score Timeline

Vote 49
0

References

JPMorgan Chase is set to report third-quarter earnings – here’s what the Street expects

JPMorgan Chase is set to report third-quarter earnings – here’s what the Street expects

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

JPMorgan Chase & Co. Q3 2025 Financial Results

JPMorgan Chase & Co. Q3 2025 Financial Results

JPMorganChase lifts 2025 NII, expense guidance; Q3 earnings beat on strong activity (JPM:NYSE)

JPMorganChase lifts 2025 NII, expense guidance; Q3 earnings beat on strong activity (JPM:NYSE)

PetMeds® Files Form 10-K for Fiscal 2025

PetMeds® Files Form 10-K for Fiscal 2025

Related Topics

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Top 1,068 Internet News Today

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement